Skip to main content

Advertisement

Log in

Reversible diabetes mellitus during growth hormone therapy in chronic renal failure

  • Brief report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract.

A 12-year-old girl with short stature due to idiopathic Fanconi syndrome and chronic renal failure was treated with recombinant human growth hormone (rhGH). There was no family history of diabetes mellitus and the glucose tolerance before treatment was normal. Intravenous glucose tolerance tests were performed before, during and after treatment. Two months after starting rhGH the early phase of insulin secretion (1-+3-min values) was diminished, and the patient developed manifest diabetes mellitus with hyperglycemia and an elevated hemoglobin A1c. Following discontinuation of rhGH, glucose tolerance slowly returned to normal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received May 29, 1997; received in revised form November 5, 1997; accepted November 12, 1997

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filler, G., Franke, D., Amendt, P. et al. Reversible diabetes mellitus during growth hormone therapy in chronic renal failure. Pediatr Nephrol 12, 405–407 (1998). https://doi.org/10.1007/s004670050475

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s004670050475

Navigation